Pharmacologic rationale for treatments of peritoneal surface malignancy from colorectal cancer
Open Access
- 1 January 2010
- journal article
- Published by Baishideng Publishing Group Inc. in World Journal of Gastrointestinal Oncology
- Vol. 2 (1), 19-30
- https://doi.org/10.4251/wjgo.v2.i1.19
Abstract
Pharmacologic rationale for treatments of peritoneal surface malignancy from colorectal cancerKeywords
This publication has 91 references indexed in Scilit:
- Heterogeneous activity of cytotoxic drugs in patient samples of peritoneal carcinomatosisEuropean Journal of Surgical Oncology, 2008
- Evaluation of the risk of contamination of surgical personnel by vaporization of oxaliplatin during the intraoperative hyperthermic intraperitoneal chemotherapy (HIPEC)European Journal of Surgical Oncology, 2007
- Investigations on safety of hyperthermic intraoperative intraperitoneal chemotherapy (HIPEC) with Mitomycin CEuropean Journal of Surgical Oncology, 2006
- A Systematic Review on the Efficacy of Cytoreductive Surgery and Perioperative Intraperitoneal Chemotherapy for Pseudomyxoma PeritoneiAnnals of Surgical Oncology, 2006
- Laparoscopic intraperitoneal hyperthermic chemotherapy for palliation of debilitating malignant ascitesEuropean Journal of Surgical Oncology, 2006
- Neoadjuvant treatment of gastric cancer with peritoneal disseminationEuropean Journal of Surgical Oncology, 2006
- High Intra-abdominal Pressure Enhances the Penetration and Antitumor Effect of Intraperitoneal Cisplatin on Experimental Peritoneal CarcinomatosisAnnals of Surgery, 2006
- Surgical trauma and peritoneal recurrence of colorectal carcinomaEuropean Journal of Surgical Oncology, 2005
- Pre-clinical study of the epinephrine–cisplatin association for the treatment of intraperitoneal carcinomatosisEuropean Journal of Surgical Oncology, 2001
- Peritoneal seeding following potentially curative resection of colonic carcinomaDiseases of the Colon & Rectum, 1991